Germany - Pharmaceuticals

Description

The purpose of this announcement is to conclude pharmaceutical discount agreements in accordance with Section 130a (8) SGB V for the active substance(s) listed under point II.1.1). It does not constitute the award of public contracts within the meaning of Directive 2014/24/EU or Sections 97 ff GWB. Any pharmaceutical company may become a contracting party pursuant to Section 4 (18) AMG. According to the case law of the ECJ, such authorization procedures are not necessarily subject to public procurement law, as there is no competition due to the lack of a selection decision. The announcement serves as an invitation to conclude discount agreements with conditions that apply equally to all contractual partners and are not dispositive, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point named under I.3).
The earliest start of the contract is 01.12.2023, provided that the signed contract and the required declarations have been received by the contact point named under I.3) by 08.11.2023. The information in IV.2.2) refers to this. In the event of later receipt, the contract shall commence on the 1st of the month following the month in which the signed contract and the required declarations or evidence are received by the contact point named under I.3), provided that they are received by the 5th of each month; otherwise on the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contracts are concluded for the active substance(s) or combination(s) of active substances as part of an award procedure. The contracts end on 30.11.2025.

Opportunity closing date

03 October 2025

Value of contract

to be confirmed